# Pacira Pharmaceuticals

Pacira Pharmaceuticals is a Specialty pharmaceutical (non-opioid pain management) based in Bala Cynwyd, United States.

## Overview

- **Organization type:** Specialty pharmaceutical (non-opioid pain management)
- **Headquarters:** Bala Cynwyd, United States
- **Region:** North America
- **Address:** Bala Cynwyd, PA, United States
- **Founded:** 1985
- **Assets under management:** Undisclosed
- **Website:** pacira.com
- **LinkedIn:** https://www.linkedin.com/company/pacira-pharmaceuticals

## Regulatory record

- **Reports private funds:** No

## About

Pacira Pharmaceuticals was founded in 1985 as a specialty pharmaceutical company, but its modern identity was shaped under David Stack, who took over as CEO in 2008. The wealth origin is corporate — the firm is publicly traded on the NASDAQ under the ticker PCRX. Stack shifted the focus to non-opioid pain management, a strategic bet that paid off with the FDA approval of Exparel (bupivacaine liposome injectable suspension) in 2011. Pacira's strategy mixes internal R&D with acquisitions and commercial partnerships. Asset classes include branded pharmaceuticals, drug-device combination products, and a pipeline of candidates targeting post-surgical and acute pain. Exparel accounted for roughly 90% of 2023 revenue (per SEC filings, 2023). Geographic footprint is predominantly US-based, with some international licensing deals in Canada and Europe. Confirmed partners include Vertex Pharmaceuticals for joint research and third-party manufacturers for supply chain. As of 2025, Pacira employs around 1,200 people, per public disclosures. The firm operates no adjacent vehicles like a foundation or VC arm. Recent activity: October 2024: Announced FDA approval of a new formulation of Exparel for nerve blocks (per Pacira press release, October 2024). Pacira's structural differentiator is its singular focus on opioid-sparing therapies, which positions it at the center of a regulatory and public health push against opioid overprescription. The company holds over 100 patents protecting its liposomal drug delivery technology, creating a moat around its lead product until at least 2029.

## Sectors

- Pharmaceuticals
- Biotech
- Healthcare Services

## People

- David Stack — CEO, President, Chairman
- Frank Ross — CFO

## Questions

### Who runs investment decisions at Pacira Pharmaceuticals?

Investment decisions are made by the executive team, led by CEO David Stack, along with the board of directors. The firm is publicly traded, so capital allocation is influenced by shareholder returns and regulatory filings (per SEC filings, 2023).

### How does Pacira source proprietary deal flow?

Pacira sources through internal R&D, acquisitions of complementary assets (e.g., the 2021 acquisition of Flexion Therapeutics for $1.1 billion), and licensing agreements with biotech firms (per SEC filings, 2021).

### Does Pacira participate in fund commitments or only direct deals?

Pacira does not participate in fund commitments. It operates as an operating company, making direct investments in R&D, M&A, and commercial activities (per public disclosures).

### What investment stages does Pacira typically target?

Pacira focuses on late-stage clinical assets and commercial-stage products with near-term revenue potential. It also acquires companies with approved or near-approval pain management drugs (per SEC filings).

### How is Pacira related to its manufacturing partnerships?

Pacira relies on third-party contract manufacturing organizations for some production, while maintaining internal manufacturing capacity at its New Jersey facility. Regulatory filings detail these relationships (per SEC filings, 2023).

## Related profiles

- [Magnit](https://altss.com/profile/magnit)
- [Rotor Capital Partners](https://altss.com/profile/rotor-capital-partners-llc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/pacira-pharmaceuticals

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology